NVIC Articles

side-panel

Disease-Vaccine-Landing-Page/side-panel

Latest articles

Browse Articles

Placeholder image
Page

A study pending peer review that was conducted by the Cleveland Clinic in early 2023 found that during the time when Omicron variant XBB was the most dominant circulating strain,...

Placeholder image
Page

A COVID-19 vaccine using viral vector technology, Sputnik V, developed in partnership between the Russian research institution, the Gamaleya National Center of Epidemiology and Microbiology, and the Russian Direct Investment...

Placeholder image
Page

Convidicea. CanSino Biologics, Inc. of Tianjin, China, in partnership with China’s Academy of Military Medical Sciences’ Institute of Biotechnology, also began development of a COVID-19 vaccine, Convidicea (Ad5-nCoV), that employs...

Placeholder image
Page

AstraZeneca-University of Oxford COVID-19 vaccineA vaccine development team from the University of Oxford in the United Kingdom endeavored to make an experimental COVID-19 vaccine candidate by the end of the...

Placeholder image
Page

Maryland-based Novavax Inc, a biotechnology company which, prior to its COVID-19 vaccine, had never successfully delivered a product to market,  developed an experimental vaccine using recombinant nanoparticle technology. Referred to...

Placeholder image
Page

In March 2020, Janssen/Johnson & Johnson announced that it had expanded its partnership with BARDA to reach its goal of providing one billion COVID-19 vaccine doses. Company officials reported that...

Placeholder image
Page

When the mRNA COVID-19 vaccines were initially authorized, they were recommended to be given intramuscularly (IM) in a two-dose series. Doses of the Pfizer-BioNTech vaccine were recommended to be administered...

Placeholder image
Page

Another experimental mRNA COVID-19 vaccine developed in a partnership between U.S. based pharmaceutical giant Pfizer, and German drug maker BioNTech, began human trials in late April 2020 in Germany. In...

Placeholder image
Page

Messenger RNA (mRNA) vaccines inject human cells with mRNA, usually within lipid nanoparticles, to stimulate cells in the body to become manufacturers of viral proteins.    In March 2020, a...

Placeholder image
Page

Drug companies and government agencies racing to be the first to license a COVID-19 vaccine, began using different technology platforms to create experimental vaccines: inactivated virus, attenuated virus, recombinant protein...

Topics
Select disease / vaccine